on Biophytis (EPA:ALBPS)
Biophytis Highlights Longevity Innovation at ARC 2025
Biophytis SA, a leader in therapies for obesity, sarcopenia, and longevity, is participating in the World Aging & Rejuvenation Conference 2025 in Vienna. Dr. Cendrine Tourette from Biophytis will present on their lead drug candidate, BIO101, focusing on its role in combating sarcopenia to enhance mobility and life quality for aging populations.
Biophytis plans to leverage conference exposure to enhance its presence in the growing longevity market. They aim to strengthen scientific and commercial partnerships, enhancing their status as a dynamic biotech player in Europe. The conference provides a crucial platform for Biophytis to validate its clinical plans and expand its professional network.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Biophytis news